We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Enabling the development of serum TTR as a biomarker for treatment of ATTR amyloidosis PC103 (#151)

Treatment-related Early Increase in Serum TTR is Associated With Lower Cardiovascular Hospitalization in ATTR-CM: Insights From ATTRibute-CM OC10 (#282)

Early Increase in Serum Transthyretin Level is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM PC130 (#321)

The Impact of Frailty and Cardiac Amyloid Burden on 6-minute walk distance in ATTR cardiomyopathy. PC62 (#323)

Daily life in patients with hereditary transthyretin amyloidosis: a qualitative study. PC29 (#1)

Cardiac amyloidosis in elderly with positive scintigraphy and monoclonality: a diagnostic dilemma  PB51 (#26)

Comparison of the Simoa and MSD R-PLEX assay to assess serum neurofilament light chain levels in hereditary transthyretin amyloidosis PB30 (#225)

Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Results from the ATTRibute-CM Clinical Trial OC7 (#281)

Prevalence of frailty in a contemporary population of ATTR cardiac amyloidosis PC80 (#562)